Kancera AB

Kancera AB is a biotech company focused on developing and selling drug candidates with primary indication to cure or slow the development of cancer and inflammatory diseases. Cardiovascular injuries associated with myocardial infarction is an example of an inflammation that Kancera AB's drug candidates can counteract. We start with a new treatment concept and end with a patented drug candidate offered for sale to major pharmaceutical and biotech companies.

The results from the recently completed Phase I clinical trial in Kancera's most developed project, the Fractalkine project, confirm that KAND567 blocks the Fractalkine system and is well tolerated in healthy subjects. Thus, the company sees a strong foundation for further development of KAND567 Phase IIa studies against inflammatory diseases and cancer.

Kancera was founded in spring 2010. The share is traded on NASDAQ OMX First North since 2011 and the number of share holders were approximately 7300 as of March 29, 2018. Kancera’s laboratories are situated in the Karolinska Institute Science Park in Stockholm, Sweden.